Purpose: Radiation pneumonitis (RP) is a dose-limiting toxicity for patients undergoing radiotherapy (RT) for lung cancer, however, the optimal practice for diagnosis, management, and follow-up for RP remains unclear. We thus sought to establish expert consensus recommendations through a Delphi Consensus study.
Methods: In Round 1, open questions were distributed to 31 expert clinicians treating thoracic malignancies.
Clin Oncol (R Coll Radiol)
October 2023
Aims: Previous work found that during the first wave of the COVID-19 pandemic, 34% of patients with lung cancer treated with curative-intent radiotherapy in the UK had a change to their centre's usual standard of care treatment (Banfill et al. Clin Oncol 2022;34:19-27). We present the impact of these changes on patient outcomes.
View Article and Find Full Text PDFBackground: STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic patients using, as primary outcome, metastatic progression-free survival (mPFS), an externally demonstrated surrogate for overall survival.
Methods: Standard of care (SOC) was androgen deprivation therapy with or without radical prostate radiotherapy.
Objectives: To identify consensus on patient prioritisation for rectal hydrogel spacer use during radiation therapy for the treatment of prostate cancer in the UK.
Design: Delphi study consisting of two rounds of online questionnaires, two virtual advisory board meetings and a final online questionnaire.
Setting: Radical radiation therapy for localised and locally advanced prostate cancer in the UK.